Assessment of Safety and Effectiveness of Oral Multiple Sclerosis Medication

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2019 Nov 11

PMID 31707408

Citations 1

Authors

Abdulrahman M Al Turaiki

Maha A Al Ammari

Dalal A Alabdulkarim

Abdullah U Althemery

Affiliations

Soon will be listed here.

Abstract

Objectives: To assess the effectiveness and safety profile of the new disease modifying drugs (fingolimod, teriflunomide, and dimethyl fumarate) at a local hospital in Riyadh, Saudi Arabia.

Methods: This is a retrospective cohort, where institutional review board approval was granted in December 2015. The study was conducted at King Abdulaziz Medical City Research Center, Riyadh, Saudi Arabia. Demographic variables (age, gender, disease onset, and duration on medication), clinical variables (medication side effects and radiological findings), in addition to relapse frequency per year was collected.

Results: Fifty-seven patients' records were retrieved from the pharmacy and included in the analysis. Eight patients were on teriflunomide, 5 patients on dimethyl fumarate and 44 patients on fingolimod were enrolled. The patients' average age was 32.5 years with female gender representing 63% the study population. Annual relapse rates were 0.24, 0.34, and 0.5 per patient per year for those taking fingolimod, dimethyl fumarate, and teriflunomide, correspondingly, lymphopenia (91.4%), neutropenia (23%), and bradycardia (16%) were the most reported side effects for fingolimod therapy.

Conclusion: The study results were able to capture the effectiveness rate for the targeted treatment in the studied population, with the frequency of incidence of side effects. However, as these results cannot be generalized for the entire Saudi population.

Citing Articles

Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing-Remitting Multiple Sclerosis.

AlShamrani F, Zafar A, Alsawad R, Yasawy Z, Shahid R, Nazish S Saudi J Med Med Sci. 2024; 12(4):299-305.

PMID: 39539793 PMC: 11556514. DOI: 10.4103/sjmms.sjmms_148_24.

References

Rotstein D, Healy B, Malik M, Chitnis T, Weiner H . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2014; 72(2):152-8. DOI: 10.1001/jamaneurol.2014.3537. View

Algahtani H, Shirah B, Abobaker H, Alghanaim N, Kamel F . Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia. Clin Neuropharmacol. 2018; 41(6):199-201. DOI: 10.1097/WNF.0000000000000305. View

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y . Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2016; 3:CD009882. PMC: 10493042. DOI: 10.1002/14651858.CD009882.pub3. View

Kingwell E, Marriott J, Jette N, Pringsheim T, Makhani N, Morrow S . Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013; 13:128. PMC: 3856596. DOI: 10.1186/1471-2377-13-128. View

Castro-Borrero W, Graves D, Frohman T, Flores A, Hardeman P, Logan D . Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2012; 5(4):205-20. PMC: 3388530. DOI: 10.1177/1756285612450936. View

Pfeuffer S, Ruck T, Kleinschnitz C, Wiendl H, Meuth S . Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015. Expert Rev Neurother. 2016; 16(6):689-700. DOI: 10.1080/14737175.2016.1176531. View

Miller A . Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther. 2015; 37(10):2366-80. DOI: 10.1016/j.clinthera.2015.08.003. View

Hua L, Fan T, Conway D, Thompson N, Kinzy T . Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler. 2018; 25(5):699-708. DOI: 10.1177/1352458518765656. View

Naegelin Y, Rasenack M, Andelova M, von Felten S, Fischer-Barnicol B, Amann M . Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Mult Scler Relat Disord. 2018; 25:14-20. DOI: 10.1016/j.msard.2018.07.005. View

10.

Khatri B . Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016; 9(2):130-47. PMC: 4784254. DOI: 10.1177/1756285616628766. View

11.

Lemus H, Warrington A, Rodriguez M . Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair. Neurol Clin. 2017; 36(1):1-11. PMC: 7125639. DOI: 10.1016/j.ncl.2017.08.002. View

12.

La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S . Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev. 2012; 1:CD005181. PMC: 11627149. DOI: 10.1002/14651858.CD005181.pub3. View

13.

Dutta R, Trapp B . Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014; 27(3):271-8. PMC: 4132635. DOI: 10.1097/WCO.0000000000000094. View

14.

Ayzenberg I, Hoepner R, Kleiter I . Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag. 2016; 12:261-72. PMC: 4767105. DOI: 10.2147/TCRM.S65558. View

15.

Vagberg M, Axelsson M, Birgander R, Burman J, Cananau C, Forslin Y . Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurol Scand. 2016; 135(1):17-24. PMC: 5157754. DOI: 10.1111/ane.12667. View

16.

Guarnera C, Bramanti P, Mazzon E . Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2017; 11:2193-2207. PMC: 5546180. DOI: 10.2147/DDDT.S137572. View

17.

Bohlega S, Inshasi J, Al Tahan A, Madani A, Qahtani H, Rieckmann P . Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol. 2013; 260(12):2959-63. PMC: 3843364. DOI: 10.1007/s00415-013-6876-4. View

18.

Lublin F, Reingold S, Cohen J, Cutter G, Soelberg Sorensen P, Thompson A . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3):278-86. PMC: 4117366. DOI: 10.1212/WNL.0000000000000560. View

19.

Tanaka M, Park K, Tanaka K . Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Mult Scler. 2013; 19(9):1244-5. DOI: 10.1177/1352458512472750. View

20.

Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J . Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin. 2015; 31(7):1349-61. DOI: 10.1185/03007995.2015.1047750. View